Dupixent results in prurigo nodularis confirm efficacy

28 March 2022

French drugmaker Sanofi (Euronext: SAN) and partner Regeneron (Nasdaq: REGN) have announced positive results from the Phase III PRIME2 trial of Dupixent (dupilumab) at the American Academy of Dermatology (AAD) 2022 Annual Meeting.

The companies previously announced top-line results from PRIME2 and a second trial called PRIME investigating the use of Dupixent in adults with uncontrolled prurigo nodularis.

"These positive results are the first time a Phase III trial has demonstrated that targeting key drivers of type 2 inflammation, IL-4 and IL-13, with dupilumab significantly improved itch and skin lesions in this highly burdensome disease"In both trials, Dupixent significantly reduced itch and skin lesions compared to placebo, and the data will form the basis of regulatory submissions around the world in prurigo nodularis, which are planned to begin in the first half of 2022. This could add to previously-approved indications in atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyps.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK